Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05139706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Montreal Immune-Related Adverse Events (MIRAE) Study

Study acronym: MIRAE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. 4 versions Re-verified since Nov 30, 2021, no change to tracked fieldsv2-v5
  2. Study First Submitted
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.
Trial Details
NCT Number NCT05139706
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions
(from sponsor)		 Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
Related terms Autoimmune Diseases, Diabetes Mellitus, Insulin-Dependent, 12, Immune System Diseases, Inflammation, Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov